Literature DB >> 35702584

Expanded newborn bloodspot screening: developed country examples and what can be done in Turkey.

Çağlar Fidan1, Hüseyin Örün1, Aslı Begüm Alper2, Çiğdem Naz Ünver2, Ömer Can Şahin2, Zeynep Uğurlu2, Recep Akdur1, Domenica Taruscio3.   

Abstract

Bloodspot screening in newborns is an exemplary public health intervention as it is essential secondary prevention with proven efficacy and benefit for the early diagnosis and prompt treatment of rare diseases. In this mini review, newborn bloodspot screening (NBS) programs of 12 countries were examined in terms of the extent of diseases/disorders screened to form recommendations for Turkey's expanded newborn screening program. Essentially, Turkey and 11 selected countries' official policies/ national programs or strategies in terms of newborn screening and the number of diseases/conditions screened were examined. The current status of spinal muscular atrophy (SMA) screening was also checked through the SMA NBS Alliance. In addition, WHO and EURORDIS guidelines for newborn screening were also reviewed. On the Pubmed database, following the search strategy "((newborn screening[Title/Abstract]) OR (newborn screening program[Title/Abstract])) OR (newborn blood spot screening[Title/Abstract])" in the PubMed database from 1 January 2008 to 1 December 2021. Diseases that will be recommended to be included in the Turkish national newborn bloodspot screening program will be presented by evaluating the updated criteria of Wilson and Jungner by constructing international comparisons. The number of diseases/disorders screened by the inspected 12 countries is eminently variable and ranges from 5 in Turkey to 51 in New York, United States of America (USA). Acknowledging the programs of other countries, it is evident that Turkey must advance its program by evaluating the epidemiological data in Turkey, the health workforce, and infrastructure while relying on the updated screening criteria. The newborn bloodspot screening program should be expanded based on the cost estimates and implemented starting with pilot applications and the diseases/disorders that are deemed appropriate should be included in the national program. 2022, International Research and Cooperation Association for Bio & Socio - Sciences Advancement.

Entities:  

Keywords:  dried blood spots; neonatal screening; newborn screening; rare diseases; secondary prevention

Year:  2022        PMID: 35702584      PMCID: PMC9161126          DOI: 10.5582/irdr.2022.01039

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  25 in total

1.  Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2. From screening laboratory results to treatment, follow-up and quality assurance.

Authors:  Peter Burgard; Kathrin Rupp; Martin Lindner; Gisela Haege; Tessel Rigter; Stephanie S Weinreich; J Gerard Loeber; Domenica Taruscio; Luciano Vittozzi; Martina C Cornel; Georg F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2012-04-28       Impact factor: 4.982

2.  Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result.

Authors:  J Gerard Loeber; Peter Burgard; Martina C Cornel; Tessel Rigter; Stephanie S Weinreich; Kathrin Rupp; Georg F Hoffmann; Luciano Vittozzi
Journal:  J Inherit Metab Dis       Date:  2012-05-03       Impact factor: 4.982

3.  The development and organization of newborn screening programs in Turkey.

Authors:  Başak Tezel; Dilek Dilli; Hilal Bolat; Hatice Sahman; Sema Ozbaş; Deniz Acıcan; Mustafa Ertek; Mehmet Rıfat Köse; Uğur Dilmen
Journal:  J Clin Lab Anal       Date:  2013-12-27       Impact factor: 2.352

4.  Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years.

Authors:  Anne Andermann; Ingeborg Blancquaert; Sylvie Beauchamp; Véronique Déry
Journal:  Bull World Health Organ       Date:  2008-04       Impact factor: 9.408

5.  Cost-effectiveness of expanded newborn screening in Texas.

Authors:  Simrandeep K Tiwana; Karen L Rascati; Haesuk Park
Journal:  Value Health       Date:  2012-06-07       Impact factor: 5.725

6.  The Italian National Rare Diseases Registry.

Authors:  Domenica Taruscio; Yllka Kodra; Gianluca Ferrari; Luciano Vittozzi
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

7.  Long-term outcome of expanded newborn screening at Boston children's hospital: benefits and challenges in defining true disease.

Authors:  Yuval E Landau; Susan E Waisbren; Lawrence M A Chan; Harvey L Levy
Journal:  J Inherit Metab Dis       Date:  2017-01-04       Impact factor: 4.982

Review 8.  Rare Diseases: Joining Mainstream Research and Treatment Based on Reliable Epidemiological Data.

Authors:  Stephen C Groft; Manuel Posada de la Paz
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

9.  Performance of Expanded Newborn Screening in Norway Supported by Post-Analytical Bioinformatics Tools and Rapid Second-Tier DNA Analyses.

Authors:  Trine Tangeraas; Ingjerd Sæves; Claus Klingenberg; Jens Jørgensen; Erle Kristensen; Gunnþórunn Gunnarsdottir; Eirik Vangsøy Hansen; Janne Strand; Emma Lundman; Sacha Ferdinandusse; Cathrin Lytomt Salvador; Berit Woldseth; Yngve T Bliksrud; Carlos Sagredo; Øyvind E Olsen; Mona C Berge; Anette Kjoshagen Trømborg; Anders Ziegler; Jin Hui Zhang; Linda Karlsen Sørgjerd; Mari Ytre-Arne; Silje Hogner; Siv M Løvoll; Mette R Kløvstad Olavsen; Dionne Navarrete; Hege J Gaup; Rina Lilje; Rolf H Zetterström; Asbjørg Stray-Pedersen; Terje Rootwelt; Piero Rinaldo; Alexander D Rowe; Rolf D Pettersen
Journal:  Int J Neonatal Screen       Date:  2020-06-27

Review 10.  Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence.

Authors:  Donald Waters; Davies Adeloye; Daisy Woolham; Elizabeth Wastnedge; Smruti Patel; Igor Rudan
Journal:  J Glob Health       Date:  2018-12       Impact factor: 4.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.